Guardant Health, Inc. $GH Shares Sold by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust reduced its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 0.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 519,545 shares of the company’s stock after selling 4,387 shares during the period. Guardant Health comprises 2.3% of Emerald Mutual Fund Advisers Trust’s investment portfolio, making the stock its 3rd largest holding. Emerald Mutual Fund Advisers Trust owned approximately 0.39% of Guardant Health worth $47,990,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its position in shares of Guardant Health by 20.2% during the first quarter. Principal Financial Group Inc. now owns 184,846 shares of the company’s stock worth $17,074,000 after acquiring an additional 31,064 shares during the period. J. Safra Sarasin Holding AG acquired a new stake in shares of Guardant Health in the first quarter valued at $548,000. Teachers Retirement System of The State of Kentucky boosted its holdings in Guardant Health by 11.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 153,253 shares of the company’s stock valued at $14,155,000 after purchasing an additional 15,782 shares during the period. Fifth Third Bancorp boosted its holdings in Guardant Health by 1,344.7% in the first quarter. Fifth Third Bancorp now owns 59,303 shares of the company’s stock valued at $5,478,000 after purchasing an additional 55,198 shares during the period. Finally, Hsbc Holdings PLC grew its stake in Guardant Health by 1,069.6% during the 1st quarter. Hsbc Holdings PLC now owns 98,843 shares of the company’s stock worth $9,130,000 after purchasing an additional 90,392 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the completion of the sale, the director owned 11,048 shares in the company, valued at $1,449,055.68. The trade was a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the transaction, the chief financial officer directly owned 47,509 shares of the company’s stock, valued at $6,110,607.58. This trade represents a 4.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 708,681 shares of company stock worth $90,566,438. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

NASDAQ:GH opened at $158.40 on Tuesday. The stock has a 50-day simple moving average of $128.92 and a 200-day simple moving average of $108.75. The stock has a market cap of $21.00 billion, a P/E ratio of -46.73 and a beta of 1.59. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $174.08.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GH. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Thursday, July 2nd. The Goldman Sachs Group started coverage on Guardant Health in a research report on Friday, June 5th. They set a “buy” rating and a $165.00 price objective for the company. Evercore reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a report on Monday, July 6th. JPMorgan Chase & Co. lifted their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Guggenheim boosted their price target on shares of Guardant Health from $135.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and a consensus price target of $155.70.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.